Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2007.02.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fertility Sparing in Endometrial Cancer: Where Are We Now?
Cancers (Basel)
January 2025
Department of Molecular and Developmental Medicine, Obstetrics and Gynecological Clinic, University of Siena, 53100 Siena, Italy.
Endometrial cancer is the most common gynecological neoplasm with an increased incidence in the premenopausal population in recent decades. This raises the problem of managing endometrial cancer in fertile women who have not yet achieved pregnancy. In these women, after careful selection, hysterectomy may be postponed in favor of conservative management if specific requirements are met.
View Article and Find Full Text PDFTranscervical resection of myoma (TCRM): Part I.
Taiwan J Obstet Gynecol
January 2025
Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Medicine, Cheng-Hsin General Hospital, Taipei, Taiwan. Electronic address:
Uterine fibroids occur frequently in women during the reproductive age, and they are rarely associated with clinical meaning because of their benign characteristics and asymptomatic clinical presentation. Sometimes, uterine fibroids are symptomatic and associated with compression syndrome, infertility, chronic pelvic pain and heavy menstrual bleeding. All need further intervention and treatment.
View Article and Find Full Text PDFState of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.
Curr Opin Obstet Gynecol
December 2024
Mount Sinai Medical Center, Miami Beach, Florida, USA.
Purpose Of Review: Endometrial cancer (EC) is rising in incidence, particularly in younger, premenopausal women, due to increasing rates of obesity and delayed childbearing. This review evaluates current and emerging endocrine therapies, with a focus on fertility-preserving approaches for early-stage EC and treatment options for advanced or recurrent disease.
Recent Findings: Fertility-sparing endocrine therapies, such as medroxyprogesterone acetate, megestrol acetate, and levonorgestrel-releasing intrauterine devices, achieve high response rates but carry recurrence risks.
Oncologic and pregnancy outcomes of fertility-sparing treatment with medroxyprogesterone acetate in women with premalignant and malignant endometrial lesions: A case series.
Eur J Surg Oncol
December 2024
Department of Anatomy, Medicine and Surgery, University of Malta, Msida, MSD2080, Malta.
Introduction: Current trends of delaying childbearing and the increasing incidence of endometrial cancer in nulliparous woman necessitate research and development of fertility sparing treatments. Hormonal therapy with progestins offers an alternative to surgical treatment for a select group of patients of reproductive-age, who wish to preserve their reproductive potential.
Materials And Methods: The study evaluates the effectiveness of medroxyprogesterone acetate therapy in patients with early-stage endometrial cancer, atypical endometrial hyperplasia or atypical polypoid adenomyoma, seeking to preserve fertility.
[Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study].
Nan Fang Yi Ke Da Xue Xue Bao
November 2024
Department of Gynecology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Article Synopsis
- The study aimed to assess the effectiveness of combining medroxyprogesterone acetate (MA) and metformin as a fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and early-stage endometrial adenocarcinoma (G1 EAC).
- It involved 60 patients who were divided into two groups, one receiving only MA and the other receiving MA plus metformin, with both treatments monitored for up to 12 months through regular follow-ups.
- Results showed similar complete response rates for both treatments, but the combined group had no significant weight gain compared to the group taking MA alone, and it led to favorable changes in certain endometrial biomarkers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!